Completed PHASE4 INTERVENTIONAL 2-arm NCT01854593

Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy

Sponsor: Nihon University

Conditions Diabetic Traction Retinal Detachment Proliferative Diabetic Retinopathy Vitreous Hemorrhage

Interventions Bevacizumab Sham injection Vitrectomy

Updated 7 times since 2017 Last updated: Jun 11, 2014 Started: May 31, 2012 Primary completion: Aug 31, 2013 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01854593, this PHASE4 trial focuses on Diabetic Traction Retinal Detachment and Proliferative Diabetic Retinopathy and remains completed. Sponsored by Nihon University, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nihon University

Data source: Nihon University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan